Sodium glucose co-transporter 2 inhibitors (SGLT2-I) can cause a life-threatening complication called Euglycemic Diabetic Ketoacidosis.
Sodium glucose co-transporter 2 inhibitors (SGLT2-I) can cause a life-threatening complication called Euglycemic Diabetic Ketoacidosis. The mechanism SGLT-2 inhibitors such as Farxiga and Jardiance, or dapagliflozin and empagliflozin, inhibit urinary glucose absorption and promote glucose excretion. This class of medications is a great adjunctive therapy for T2DM, especially those with heart failure. Keep some things are your radar. In the setting of an acute response like an infection, SGL2-i can mimic starvation states with normal serum glucose levels (< 250 mg/dL). This leads to anaerobic metabolism, increasing fatty acid and ketone production.
Check for sneaky ketones in the urine and beta-hydroxybyrate if you’re suspicious.
Hungry for more PHARMFAX, check out the other videos I’ve made. I hope you learn something new.
ALL PHARMWYZE SOURCE
www.pharmwyze.com
References can be found on website.
Follow me @pharmwyze
Twitter | Facebook | TikTok | YouTube | Instagram
Comments